Development of the Relationship between Angiogenesis and Tumor Dormancy

REFERENCES

1. ↵
   1. Naumov GN,
   2. Akslen LA,
   3. Folkman J

   . Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-1787.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Indraccolo S,
   2. Favaro E,
   3. Amadori A, et al.

   Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 2006;5:1751-1755.

   OpenUrlPubMedWeb of Science
3. ↵
   1. Herbst RS,
   2. Hess KR,
   3. Tran HT, et al.

   Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-3803.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Che G,
   2. Chen J,
   3. Liu L, et al.

   Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981. Neoplasma 2006;53:530-537.

   OpenUrlPubMedWeb of Science
5. ↵
   1. Indraccolo S,
   2. Stievano L,
   3. Minuzzo S, et al.

   Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci USA 2006;103:4216-4221.

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Udagawa T,
   2. Fernandez A,
   3. Achilles EG, et al.

   Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002;16:1361-1370.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Almog N,
   2. Henke V,
   3. Flores L, et al.

   Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006;20:947-949.

   OpenUrlCrossRefPubMed
8. ↵
   1. Heyn C,
   2. Ronald JA,
   3. Mackenzie LT, et al.

   In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006; 55:23-29.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Achilles EG,
   2. Fernandez A,
   3. Allred EN, et al.

   Heterogeneity of angiogenic activity in a human liposarcoma:a proposed mechanism for “no take” of human tumors in mice. J Natl Cancer Inst 2001;93:1075-1081.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Naumov GN,
    2. Bender E,
    3. Zurakowski D, et al.

    A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-325.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Che GW,
    2. Liu LX,
    3. Zhou QH, et al.

    The development of tumor dormancy and the mechanism. Chin J Cancer 2006;25:1315-1319 (Chinese).

    OpenUrl
12. ↵
    1. Pang R,
    2. Poon RT

    . Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242:151-167.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Shih T,
    2. Lindley C

    . Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-1802.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Wheeler C,
    2. Trevor S,
    3. Byth K, et al.

    Novel approaches in oncology at AstraZeneca. Euro J Cancer Supplements 2003;1:3-8.

    OpenUrl
15. ↵
    1. Rolin J,
    2. Régina S,
    3. Vourc’h P, et al.

    Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007; 56:273-280.

    OpenUrlCrossRefPubMedWeb of Science